Strong Independent Association of TILs with OS for Patients with ERBB2-positive Early Breast Cancer By Ogkologos - February 26, 2025 539 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from updated analysis of the ShortHER study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Mouse Study Links Immune Cells to Diarrhea Caused by Chemotherapy July 20, 2018 Scottish Soccer Star Who Just Announced Breast Cancer Diagnosis Scores Goal,... December 21, 2020 How Breast Cancer Risk Assessment Tools Work June 27, 2024 Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma... November 21, 2020 Load more HOT NEWS FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer A tribute to Professor Anne Charlton FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung... Insights Into the Biology of Response and Resistance to MAPK Pathway...
